Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2022-12-16 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于股东完成吸收合并的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the completion of a shareholder absorption merger, detailing the transfer of shares and changes in shareholder structure. It does not contain financial statements or detailed financial performance data. It is a corporate action announcement related to shareholding changes but does not fit the category of a merger filing (MA) or takeover bid (TAR) since it focuses on share transfer and shareholder structure update. The closest specific category is Major Shareholding Notification (MRQ), as it reports changes in significant share ownership levels and shareholder composition.
2022-12-16 Chinese
关于召开2022年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2022 first extraordinary general meeting of shareholders for 普洛药业股份有限公司. It details the meeting time, location, voting procedures, agenda items, and proxy voting instructions. There is no financial data or report content, only an announcement of the meeting and related procedural information. The document length is about 3,131 characters, which is relatively short and consistent with a meeting notice rather than a full report. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2022-12-06 Chinese
关于向参股公司提供财务资助展期暨关联交易事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from the independent directors of 普洛药业股份有限公司 regarding a financial assistance extension and related party transaction. It references compliance with regulatory rules and internal company procedures, and provides an independent directors' approval statement. The document is short (555 characters) and does not contain financial statements or detailed financial data. It is a formal opinion related to governance and compliance rather than a full report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory compliance-related document that does not fit other specific categories.
2022-12-06 Chinese
关于向参股公司提供财务资助展期暨关联交易事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding the pre-approval of a financial assistance extension and related party transaction involving subsidiaries and an associate company. It references regulatory rules for independent directors and stock exchange listing rules, and it is signed by the independent directors. The content is about governance and approval of related party transactions, not a financial report, earnings release, or announcement of voting results. It is not a report publication or certification but a governance-related document. Therefore, the best fitting category is Board/Management Information (MANG), as it involves board-level approval and opinions on corporate governance matters.
2022-12-06 Chinese
关于向参股公司提供财务资助暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 普洛药业股份有限公司 regarding the extension of financial assistance to an associate company, 亿帆优胜美特医药科技有限公司, which constitutes a related party transaction. It details the transaction's background, financial figures, risk analysis, board opinions, and independent directors' opinions. The document is a formal disclosure of a related party transaction and financial support extension, not a full financial report or earnings release. It does not contain comprehensive financial statements or quarterly results but focuses on a specific capital/financing update related to the company's funding activities and related party dealings. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is 3106 characters, which is consistent with an announcement rather than a full report.
2022-12-06 Chinese
第八届董事会第十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the company's board of directors regarding decisions made at a board meeting, including approval of financial assistance to an associate company and the proposal to convene an extraordinary general meeting. It includes details about the meeting date, attendance, voting results, and compliance with company law and articles of association. There is no financial data, audit information, or report content. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2022-12-06 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.